Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Pfizer Inc.
IndexDJIA S&P500 P/E23.64 EPS (ttm)1.45 Insider Own0.10% Shs Outstand6.16B Perf Week0.85%
Market Cap211.08B Forward P/E15.43 EPS next Y2.22 Insider Trans-6.03% Shs Float6.14B Perf Month-2.25%
Income9.20B PEG12.44 EPS next Q0.52 Inst Own72.90% Short Float1.45% Perf Quarter0.50%
Sales49.12B P/S4.30 EPS this Y-14.50% Inst Trans-1.12% Short Ratio3.39 Perf Half Y14.55%
Book/sh10.85 P/B3.16 EPS next Y8.93% ROA6.80% Target Price37.13 Perf Year19.63%
Cash/sh4.50 P/C7.62 EPS next 5Y1.90% ROE15.70% 52W Range26.81 - 35.24 Perf YTD11.94%
Dividend1.12 P/FCF33.00 EPS past 5Y3.10% ROI8.90% 52W High-2.72% Beta0.75
Dividend %3.27% Quick Ratio2.20 Sales past 5Y0.10% Gross Margin81.00% 52W Low27.85% ATR0.39
Employees78300 Current Ratio2.40 Sales Q/Q-4.30% Oper. Margin28.50% RSI (14)53.92 Volatility0.86% 1.22%
OptionableYes Debt/Eq0.53 EPS Q/Q8.60% Profit Margin23.40% Rel Volume0.49 Prev Close34.36
ShortableYes LT Debt/Eq0.44 EarningsApr 28 BMO Payout57.90% Avg Volume26.23M Price34.28
Recom2.30 SMA200.83% SMA500.13% SMA2009.44% Volume12,973,467 Change-0.23%
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jan-22-13Reiterated Barclays Equal Weight $24 → $25
Nov-27-12Downgrade MKM Partners Buy → Neutral $29 → $25
Oct-05-12Reiterated MKM Partners Buy $27 → $29
Nov-01-11Downgrade Standpoint Research Buy → Hold
Oct-07-11Initiated MKM Partners Buy $20.50
Sep-14-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
Aug-10-11Upgrade Argus Hold → Buy $21
Aug-05-11Upgrade Standpoint Research Hold → Buy $21
Mar-14-11Downgrade Standpoint Research Buy → Hold
Nov-03-10Downgrade Argus Buy → Hold
May-21-10Initiated Jefferies Buy $17.80
Dec-16-09Initiated UBS Buy
May-23-15 07:07AM  Germany's Merck expects drug division to drive growth-Euro am Sonntag
May-22-15 07:58PM  Would Pfizer Buying GlaxoSmithKline Make Sense? at Investopedia
01:12PM  Esperion Therapeutics: 15 Reasons to Take Profits at
11:04AM  Could M&A Boost Pfizer More? Jefferies Thinks So
09:15AM  Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy at 24/7 Wall St.
07:43AM  In a quiet stock market, whispers of an M&A wave
06:55AM  All Eyes on Pfizer as Shareholders Await the Mega-Deal
May-21-15 05:35PM  All Eyes on Pfizer as Shareholders Await the Mega-Deal: Real M&A at Bloomberg
12:45PM  How a "PfizerKline" would impact the Triangle at
08:47AM  3 Big Pharmaceutical Stocks to Buy Right Now at TheStreet
May-20-15 02:12PM  Hedge Funds Love These 5 Big Stocks -- but Should You? at TheStreet
01:55PM  How biotechs are affecting J&J's business
11:36AM  Pfizer To See Boosting Revenues On New Drugs Growth Through 2020
08:54AM  Pfizer Would Benefit From Glaxo Takeover, Deutsche Bank Says at Bloomberg
08:11AM  Who are Pfizer's (PFE) main competitors? at Investopedia
08:08AM  JNJ's 'balance approach' accounts for success: CEO
12:18AM  [$$] Merck Could Struggle to Hit Health Care Heights at The Wall Street Journal
May-19-15 06:20PM  Like Big Dividends? 6 Steady Payers You Can Rely On at Investor's Business Daily
12:04PM  Amgen cholesterol drug could get EU green light this week Reuters
10:26AM  Merck Could Struggle to Hit Health Care Heights at The Wall Street Journal
10:00AM  Pfizer Invites Public to View and Listen to Webcast of June 2 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations Business Wire
01:40AM  MannKind's Huge Short Interest Sets Up Contrarian's Dream Buy at Forbes
May-18-15 06:15PM  Which Top Dividend Stocks Get Thumbs Up From Buffett? at Investor's Business Daily
05:27PM  5 Things Pfizer's Management Wants You to Know at Investopedia
02:29PM  Goldman: Market's going nowhere for a year at CNBC
02:08PM  Big Win for TPG on Par Pharmaceuticals at The Wall Street Journal
12:29PM  Bull Market In Animal Health Injects Zoetis With Value at Forbes
10:28AM  Barron's 2015 Income Picks at Forbes
09:12AM  Entrepreneur Touts Cheap, Safe Smoking Cessation Drug -- But Is It? at Forbes
May-15-15 02:30PM  GlycoMimetics' Leukemia Drug Gets Orphan Status in U.S. - Analyst Blog
02:22PM  Why Clovis is Getting Clobbered at
May-14-15 11:50PM  The drugs to watch in fight against cancer at Financial Times
04:02PM  HospiraPfizer Deal Update: Shareholder Approval, 2nd Request
02:32PM  Cancer data deluge
12:27PM  Pfizer Receives Request For Additional Information From FTC Regarding Proposed Acquisition Of Hospira Business Wire
09:44AM  Merck, Pfizer Cancer Fighting Drugs Show Promise: Report
09:44AM  Cancer Drug Report Shows Promise for Merck KGAA, Pfizer at Bloomberg
08:07AM  Marc Tessier-Lavigne, Ph.D. to Leave Pfizer Board of Directors Business Wire
07:13AM  Is Sir Andrew Witty The Person To Lead A Major Pharmaceutical Company? at Forbes
May-13-15 06:53PM  An Attractive M&A Play In The Busy Biotech Space at Forbes
05:53PM  10 Important Checkpoint Inhibitor Cancer Drug Abstracts from ASCO '15 at TheStreet
05:01PM  Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody Business Wire
05:00PM  Pfizer drug shows early promise in Xalkori-resistant lung cancer-study
04:01PM  The 4 Stocks That Drove the DJIA Down on Wednesday at 24/7 Wall St.
01:04PM  PFIZER INC Financials
11:53AM  Biotech investors: These are the key names to know at CNBC
11:35AM  5 New Biotech Developments Worth Watching
04:20AM  Possible Investment Contest
01:00AM  How DNA sequencing is transforming the hunt for new drugs Reuters
May-12-15 04:20PM  Pfizer Acquires Stake in Dutch Biopharmaceutical Company - Analyst Blog
02:18PM  Pfizer Buys a Minority Stake in Dutch Biotech Firm AM-Pharma at TheStreet
02:18PM  Pfizer Buys a Minority Stake in Dutch Biotech Firm AM-Pharma
09:50AM  Short Sellers Keep Strong Bets Against Big Pharma at 24/7 Wall St.
08:52AM  Pharmalot.. Pharmalittle.. Good Morning: We're Catching up on Mylan, Teva and Much More!! at The Wall Street Journal
May-11-15 04:30PM  Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company Business Wire
03:36PM  New blood tests, liquid biopsies, may transform cancer care
01:15PM  Apple, Microsoft and Google lead list of companies holding cash abroad
01:05PM  [$$] In U.K., Barriers Rising Against Foreign Deals at The Wall Street Journal
10:49AM  Pfizer Inc. (PFE), Merck & Co., Inc. (MRK), Citigroup Inc (C) Top Kahn Brothers Portfolio at Insider Monkey
08:02AM  Saudia Arabia: Home Of One Of the World's Largest Smart City? at Forbes
06:02AM  Economic Recovery is at Hand...Really!
05:05AM  What Investors Can Expect from Pfizer in 2015
04:05AM  How the Mylan Bid Stacks Up to Similar Transactions
03:04AM  Key Factors That Impact Johnson & Johnsons Forward Valuation
01:00AM  The new US office politics: funding your boss's political causes
May-10-15 09:48PM  Defenders Unite Against Cyber Threats In Healthcare at Forbes
05:50PM  In U.K., Barriers Rising Against Foreign Deals at The Wall Street Journal
May-09-15 10:05PM  Pfizer Stock Dips over 1Q15 Forward Valuation Concerns
08:09PM  10-Q for Pfizer Inc. at Company Spotlight
May-08-15 12:06PM  Pfizer Revenues Hit by Lost Exclusivity in 1Q15
12:06PM  Pfizers Exposure to Overseas Markets Soaks 1Q15 Revenues
11:20AM  ARIAD (ARIA) Q1 Loss Wider than Estimates; Iclusig Grows - Analyst Blog
11:10AM  Best U.S. Pharma Picks, Big and Small at
10:06AM  Healthcare AM Winners and Losers: May 8, 2015
May-07-15 01:59PM  Apple still on top as U.S. corporate cash holdings reach $1.73 trillion at MarketWatch
09:49AM  The FDA Is On A Quest To Rid DTC Drug Ads Of Confounding Fine Print at Forbes
09:30AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, iShares U.S. Pharmaceuticals ETF, PowerShares Dynamic Pharmaceuticals Fund and Market Vectors Pharmaceutical ETF - Press Releases
04:33AM  Pfizer Limited revenues (on a like to like basis) increases by 12% for the year ended March 31, 2015. at noodls
May-06-15 04:01PM  The 4 Stocks That Weighed on the DJIA on Wednesday at 24/7 Wall St.
03:26PM  Pfizer Appoints New Leaders for BioTherapeutics Research & Development and Rinat at noodls
01:04PM  Pfizer Appoints New Leaders for BioTherapeutics Research & Development and Rinat at noodls
12:48PM  Pfizer Appoints New Leaders for BioTherapeutics Research & Development and Rinat Business Wire
10:55AM  Stocks off lows amid higher yields, Yellen remarks on valuation at CNBC
10:00AM  Big Pharma Q1 Earnings Beat Put Pharma ETFs in Focus - ETF News And Commentary
08:14AM  GlaxoSmithKline opts to hold on to HIV business
05:53AM  Zoetis (ZTS) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
04:51AM  ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy PR Newswire
12:30AM  [$$] Zoetis Wont Tame Pharma M&A at The Wall Street Journal
12:27AM  Lawmakers Embrace Patent Tax Breaks at The Wall Street Journal
May-05-15 03:20PM  Lawmakers Embrace Patent Tax Breaks at The Wall Street Journal
01:56PM  Zoetis Won't Tame Pharma M&A at The Wall Street Journal
11:00AM  A campus brain drain in the US no one talks about at CNBC
10:50AM  Top Credit Suisse Major Pharma Stock Picks to Buy at 24/7 Wall St.
10:30AM  Pfizer, other drug giants to drive biotech
09:19AM  Transparency Is Still A Problem As Big Pharma Struggles With Its Image at Forbes
08:51AM  Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers
07:13AM  Pfizer Posts Earnings on April 28, Beats Estimates by a Penny
07:02AM  The Cancer Drug Market Just Hit $100 Billion And Could Jump 50% In Four Years at Forbes
02:45AM  Global cancer drug spending hits $100 billion in 2014-IMS Health Reuters
May-04-15 06:00PM  Cramer: Why markets rallied
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women's/men's health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has collaboration with BIND Therapeutics, Inc. to develop and commercialize multiple Accurins. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUSMAN SALLYExecutive Vice PresidentMar 12Sale34.0046,1791,570,086150,899Mar 13 10:39 AM
Dolsten MikaelPresident R&DMar 05Sale34.4658,2982,009,152355,911Mar 06 07:32 PM
READ IAN CChairman & CEOMar 05Sale34.6267,5002,336,7931,408,457Mar 06 07:19 PM
OLSON LAURIE JExecutive Vice PresidentFeb 25Option Exercise17.6921,115373,52481,240Feb 27 06:49 PM
HILL CHARLES HExecutive Vice PresidentFeb 25Option Exercise17.6922,523398,432121,572Feb 27 06:42 PM
JOHNSON RADY AExecutive Vice PresidentFeb 25Option Exercise17.6919,426343,64656,250Feb 27 06:42 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 25Option Exercise17.6932,855581,205141,441Feb 27 06:42 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 25Option Exercise17.69101,3511,792,899227,982Feb 27 06:42 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 25Option Exercise17.6923,649418,35188,933Feb 27 06:42 PM
READ IAN CChairman & CEOFeb 25Option Exercise17.69197,0723,486,2041,568,718Feb 27 06:50 PM
SUSMAN SALLYExecutive Vice PresidentFeb 25Option Exercise17.6995,7211,693,304261,233Feb 27 06:56 PM
YOUNG JOHN DGroup PresidentFeb 25Option Exercise17.6949,364873,249159,673Feb 27 06:56 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Option Exercise26.20104,0002,724,800288,775Feb 17 05:50 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Sale34.73104,0003,612,323184,775Feb 17 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 12Sale34.859,000313,66170,252Feb 13 01:50 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.3014,800507,619440,886Feb 12 04:01 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.2380,2002,744,861360,686Feb 12 04:01 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 10Sale33.789,000304,02079,252Feb 11 08:02 PM
LANKLER DOUGLAS MExecutive Vice PresidentDec 31Option Exercise18.1921,413389,502127,673Jan 05 05:17 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerDec 31Option Exercise18.1932,120584,263207,985Jan 05 05:17 PM
HILL CHARLES HExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892126,245Jan 05 05:17 PM
OLSON LAURIE JExecutive Vice PresidentDec 31Option Exercise18.1918,737340,82675,811Jan 05 05:17 PM
YOUNG JOHN DGroup PresidentDec 31Option Exercise18.1926,767486,892128,860Jan 05 05:17 PM
JOHNSON RADY AExecutive Vice PresidentDec 31Option Exercise18.1932,120584,26361,803Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892107,900Jan 05 05:16 PM
BOURLA ALBERTGroup PresidentDec 31Option Exercise18.1916,060292,131113,177Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 08Sale32.006,500208,00082,830Dec 09 10:44 AM
HILL CHARLES HExecutive Vice PresidentNov 10Sale30.188,285250,04199,478Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Option Exercise26.2021,600565,920123,462Nov 10 05:34 PM
DAMELIO FRANK AExecutive Vice PresidentNov 07Sale29.7807454,687Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Sale29.8921,600645,548101,862Nov 10 05:34 PM
READ IAN CChairman & CEOOct 30Option Exercise17.0354,585929,5831,465,906Nov 03 06:23 PM
DAMELIO FRANK AExecutive Vice PresidentOct 30Option Exercise17.0365,5021,115,499501,494Nov 03 06:23 PM
READ IAN CChairman & CEOOct 30Sale29.7667,5002,008,8001,358,862Nov 03 06:23 PM
MADDALUNA ANTHONY JExecutive Vice PresidentOct 29Sale29.562,42571,68388,987Oct 30 06:23 PM
OLSON LAURIE JExecutive Vice PresidentJun 12Option Exercise26.2036,275950,40593,010Jun 13 12:29 PM
OLSON LAURIE JExecutive Vice PresidentJun 12Sale29.5336,2751,071,27856,735Jun 13 12:29 PM